Literature DB >> 10861692

Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population.

C L Goolsby1, M Kuchnio, W G Finn, L Peterson.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of mature-appearing clonal B cells exhibiting coexpression of CD5 and CD23. In addition to the accumulation of neoplastic B cells, numerous T-cell abnormalities also occur in B-CLL patients. In this study, the presence, and distribution within the T-cell subsets, of clonal/oligoclonal T cells was studied. Multicolor flow cytometric techniques were employed using combinations of anti-CD3, anti-CD4, and anti-CD8 antibodies coupled with antibodies specific for V(alpha) and V(beta) T-cell receptor (TCR) epitopes. Molecular studies of TCR gene sequences were done to confirm the presence of clonal/oligoclonal T-cell populations. In the flow cytometric studies, examination of V(alpha)/V(beta)expression found evidence of clonal/oligoclonal expansion in 9 of 19 patients studied. In eight of the nine patients, the expansions were restricted to the CD3(+)CD8(+) cell population. Molecular analyses were performed in 16 patients, 12 of whom showed a clonal or oligoclonal pattern. Of the four patients who were negative in the molecular analyses, all demonstrated flow cytometric evidence of clonal/oligoclonal expansions. Thus, when the flow cytometric and molecular analyses were considered together, all 16 patients for whom parallel analyses were done showed evidence of clonal/oligoclonal expansions. These results confirm previous work demonstrating that the majority of B-CLL patients harbor clonal/oligoclonal expansions within the T-cell population. Additionally, based on the relative numbers of cells expressing specific V(alpha) or V(beta)epitopes, these results show that these expansions occur primarily within the CD3(+)CD8(+) T-cell population. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861692

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  16 in total

1.  Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease.

Authors:  M Lima; J Almeida; A H Santos; M dos Anjos Teixeira; M C Alguero; M L Queirós; A Balanzategui; B Justiça; M Gonzalez; J F San Miguel; A Orfão
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Authors:  Qingsong Yin; Mariela Sivina; Harlan Robins; Erik Yusko; Marissa Vignali; Susan O'Brien; Michael J Keating; Alessandra Ferrajoli; Zeev Estrov; Nitin Jain; William G Wierda; Jan A Burger
Journal:  J Immunol       Date:  2017-01-11       Impact factor: 5.422

Review 3.  Immunologic aspects of monoclonal B-cell lymphocytosis.

Authors:  Mark C Lanasa; J Brice Weinberg
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 4.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

5.  Oligoclonal TRBV gene usage among CD8(+) T cells in monoclonal B lymphocytosis and CLL.

Authors:  Mark C Lanasa; Sallie D Allgood; Karen M Bond; Jon P Gockerman; Marc C Levesque; J Brice Weinberg
Journal:  Br J Haematol       Date:  2009-03-02       Impact factor: 6.998

6.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 7.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 8.  Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Authors:  Joseph A Fraietta; Robert D Schwab; Marcela V Maus
Journal:  Semin Oncol       Date:  2016-02-09       Impact factor: 4.929

Review 9.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

10.  Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.

Authors:  Yucai Wang; Sutapa Sinha; Linda E Wellik; Charla R Secreto; Karen L Rech; Timothy G Call; Sameer A Parikh; Saad S Kenderian; Eli Muchtar; Suzanne R Hayman; Amber B Koehler; Daniel L Van Dyke; Jose F Leis; Susan L Slager; Haidong Dong; Neil E Kay; Rong He; Wei Ding
Journal:  Blood Cancer J       Date:  2021-05-10       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.